Meeting
2020 ASCO Virtual Scientific Program
Role of adjuvant chemotherapy in patients with pathological stage I NSCLC with high-risk features.
Authors
Lubina Arjyal
Gundersen Health System, La Crosse, WI
Lubina Arjyal , Dipesh Uprety , Susan M Frankki , Andrew J Borgert , David E. Marinier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9022)
DOI
10.1200/JCO.2020.38.15_suppl.9022
Abstract #
9022
Poster Bd #
215
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected non-small cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).
First Author: Akihiro Tamiya
Poster
2012 ASCO Annual Meeting
Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (p).
First Author: Jose Miguel Sanchez
Poster
2023 ASCO Annual Meeting
Thoracic SMARCA4-deficient cancer descriptors and clinicopathologic determinants of survival: Analysis of a pooled database.
First Author: Frankie Lee Powell
Poster
2018 ASCO Annual Meeting
Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): A secondary analysis of NRG Oncology RTOG 0617.
First Author: Chen Hu